A comparative analysis of Vamana and ShamanaChikitsa in prediabetes management: A randomized clinical trial

BACKGROUND

Prediabetes is a condition before manifestation of diabetes. It is associated with biochemical change in body due to disturbances in food habits, sleep patterns and sedentary lifestyle. Conventional system of medicine has limitations, however Ayurvedic medicines can be effective for management of this condition.

OBJECTIVE

To compare the efficacy of Vamana Karma (∼therapeutic emesis) followed by Darvyadi Kwatha (∼herbal decoction) with that of oral medication of Darvyadi Kwatha with lifestyle modification in reducing HbA1c of the prediabetic participants.

METHODOLOGY

After approval of IEC and registration under clinical trial registry of India, 40 patients were registered in two groups suffering from prediabetes in the trial. The primary criteria were HBA1c, FBS & PPBS along with secondary criterias like Agnibala (∼strength of digestion and metabolism), Dehabala (physical strength) and Satvabala (mental strength) relief in signs & symptoms of Prameha and quality of life (SF-36 Score).

RESULTS

Statistically significant results were observed in both the parameters: (primary & secondary) within the group [VM group (HbA1c (<0.001), FBS (<0.001) & PPBS (<0.001) and SM group (HbA1c (<0.001), FBS (<0.001) & PPBS (<0.001)] and between the group [HbA1c (P < 0.01), FBS (P < 0.01), SF-36 score (P < 0.001) as well.

CONCLUSION

The present clinical study suggests that there is significant improvement between the groups. On comparision, it was found that treating prediabete.s Shodhana was more safe & effective than Shamana.

"Ayurveda management of Palmoplantar Psoriasis (Vipadika) -a case report"

INTRODUCTION

Palmo-plantar Psoriasis is a non-infectious chronic inflammatory disease of the skin bounded to the palm and soles in extent. In Ayurveda, all skin diseases are recounted under a single rubric i.e., Kushtha (skin diseases); PPP (Palmo-plantar Psoriasis) may be correspondent with Vipadika (one of the Kshudra Kushtha described in Ayurveda), based on its clinical sign & symptom.

OBJECTIVES

The role of Ayurvedic regimen in Palmo plantar psoriasis.

METHODOLOGY

Here we are presenting a case of 68-year-old man with a long 8-year history of pruritic rashes on his both palms and soles which was diagnosed as Palmo-Plantar Psoriasis (Vipadika) and successfully managed with simple Ayurveda medicines, external application of Jivantyadi Yamaka, external washing with Triphala decoction and 3 sitting of Jalaukavacharana (Leech Application).

RESULT

The patient reported a significant improvement in the complaints of itch and rash, on the scale and erythema of the palms and soles in a span of about 3 weeks.

CONCLUSION

We, therefore, recommend the treatment of Palmo -plantar Psoriasis starting with leech application along with oral and external Ayurveda medication, and results can be seen.

AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial

Objective

The world continues to face the COVID-19 crisis, and efforts are underway to integrate traditional medicine interventions for its effective management. The study aimed to determine the efficacy of the "AYURAKSHA" kit in terms of post-interventional percentage of COVID-19 IgG positivity, immunity levels, and quality of life (QoL) against COVID-19.

Method

This was a non-randomized controlled, prospective intervention trial, done after the distribution of 80,000 AYURAKSHA kits (constituent of Sanshamani Vati, AYUSH Kadha, and Anu Taila) among Delhi police participants in India. Among 47,827 participants, the trial group (n = 101) was evaluated with the positivity percentage of IgG COVID-19 and Immune Status Questionnaire (ISQ) scores as a primary outcome and the WHO Quality of Life Brief Version (QOL BREF) scores along with hematological parameters as a secondary outcome in comparison to the control group (n = 71).

Results

The data showed that the percentage of COVID-19 IgG positivity was significantly lower in the trial group (17.5 %) as compared to the control group (39.4 %, p = 0.003), indicating the lower risk (55.6%) of COVID-19 infection in the trial group. The decreased incidence (5.05%) and reduced mortality percentage (0.44%) of COVID-19 among Delhi police officers during peak times of the pandemic also corroborate our findings. The ISQ score and WHO-QOL BREF tool analysis showed the improved scores in the trial group when compared with the controls. Furthermore, no dysregulated blood profile and no increase in inflammation markers like C-reactive protein, erythrocyte sedimentation rate, Interleukin-6 (IL-6) were observed in the trial group. However, significantly enhanced (p = 0.027) IL-6 levels and random blood sugar levels were found in the control group (p = 0.032), compared to a trial group (p = 0.165) post-intervention. Importantly, the control group showed more significant (p = 0.0001) decline in lymphocyte subsets CD3⁺ (% change = 21.04), CD4⁺ (% change = 20.34) and CD8⁺ (% change = 21.54) levels than in trial group, confirming more severity of COVID-19 infection in the control group.

Conclusion

The AYURAKSHA kit is associated with reduced COVID-19 positivity and with a better quality of life among the trial group. Hence, the study encourages in-depth research and future integration of traditional medicines for the prevention of the COVID-19 pandemic.

Clinical trial registration

http://ctri.nic.in/, identifier: CTRI/2020/05/025171.

Efficacy of Vamana Karma (therapeutic emesis) followed by Darvyadi Kwatha (herbal decoction) in the management of prediabetes (Prameha) - A single-arm clinical trial

Background

Prediabetes is an alarming condition to control and prevent from developing diabetes mellitus which occurs due to the change in lifestyle and food habits. Timely untreated prediabetes turn into type-2 diabetes mellitus within a year and systemic complications such as retinopathy, nephropathy, and neuropathy could occur and in later stage multi system damage could take place.

Aims

The ai of this study is to evaluate the efficacy of Vamana Karma (therapeutic emesis) with Ikshuvaku Yoga and followed by oral administration of Darvyadi Kwatha (herbal decoction) in the management of prediabetes.

Materials and methods

After approval of IEC and registration under clinical trial registry of India, 20 patients suffering from prediabetes were registered in the trial. Diagnosis criteria were hemoglobin A1c (HBA1c), fasting blood sugar (FBS) and postprandial blood sugar (PPBS), and assessment criteria includes HBA1c, FBS, PPBS, along with improvement in Agnibala (strength of digestion and metabolism), Dehabala (physical strength) and Satvabala (mental strength), relief sign and symptom of prediabetes (Prameha), and improvement in quality of life (SF-36 Score). Classical Vamana Karma followed by oral administration of Darvyadi Kwatha was done. Total duration of treatment was 45 days and last follow-up was done on the 120th day. Student's t- test was used for the analysis of parametric data.

Results

After the treatment were observed that there is improvement in subjective as well as in objective parameters. Statistically highly significant result was observed in HBA1c (BT [day 0] Mean score 6.25 and AT [day 120] 5.63 [P < 0.001]), FBS (BT [day 0] mean score 120.05 and AT [day 120] 93.31 [P < 0.001]) and PPBS (BT [day 0] mean score 165.26 and AT [day 120] 112.84 [P < 0.001]), sign and symptoms of Prameha, Dehabala, Agnibala, Satvabala, and quality of life (SF-36 Score).

Conclusion

The present clinical study concludes that therapeutic emesis (bio purification) followed by Darvyadi Kwatha as internal medicine shows significant result in treating prediabetes (Prameha) safely and effectively also control and prevent developing diabetes mellitus. None of the patient converted to diabetes mellitus on the day 120.

A clinical study on the effect of Triphaladi Kala Basti with Arjuna Punarnavadi Ghanavati in the management of essential hypertension

Introduction:

Hypertension, one of the grave conditions, accounts for 6% of deaths worldwide. In 2010 increased blood pressure was the cause of an estimated 9.4 million deaths. According to Ayurveda, systemic arterial hypertension can be considered as Tridoshaja condition with predominance of Vata and Pitta along with invovment of Rasa, Rakta and Meda. Basti Karma a medicated enema procedure is the best treatment for vitiated VataDosha and it regulates the movement of VataDosha

Objectives:

The present study was conducted to evaluate effect of TriphaladiKalaBasti procedure given along with ArjunaPunarnavadiGhanavati in the management of essential hypertension.

Materials and Methods:

Fifteen patients who were diagnosed cases of essential hypertension as per the 7^th JNC and World Health Organization criteria for diagnosis of hypertension were treated with Triphaladi Basti followed by oral administration of Arjuna Punarnavadi Ghanavati.

Results:

Administration of Basti and Arjuna Punarnavadi Ghanavati were effective in reducing both systolic and diastolic blood pressure level which was highly significant (P < 0.001).

Conclusion:

Triphaladi Kala Basti procedure along with oral administration of Arjuna Punarnavadi Ghanavati is moderatly effective in management of systemic arterial hypertension.

A standard controlled clinical study on Virechana Karma and Lekhana Basti in the management of dyslipidemia (Medoroga)

Background:

Dyslipidemia, a major risk factor of coronary heart disease, is the leading single cause of death in the world. Currently available hypolipidemic agents have been associated with a large number of side effects. The radical Ayurveda Samshodhana Chikitsa as a treatment protocol can provide better effect. Therefore, the present study was designed to evaluate the effect of Virechana Karma and Lekhana Basti in dyslipidemia.

Objectives:

To evaluate the effect of Virechana Karma and Lekhana Basti in the management of dyslipidemia (Medoroga).

Materials and Methods:

Ninety patients of either sex in the age group of 20–60 years, fulfilling the study criteria were included in the study. The patients were randomly divided into three groups (thirty patients each). Virechana Karma was administered to patients in group A, Lekhana Basti was administered in group B and tablet Atorvastatin in group C. The effect of treatment was assessed by analyzing the complete lipid profile after completion of treatment and after the follow up in comparison to base line score.

Results:

All the three groups showed statistically highly significant result in the lipid profile after the treatment and after the follow up.

Conclusion:

Virechana Karma is effective in reducing triglycerides level, where as Lekhana Basti is effective in reducing the cholesterol level in particular.